Post progression survival in glioblastoma: where are we?

Autor: Damiano Balestrini, Raffaele Agati, Marco Bartolotti, Gianluca Marucci, Mario Ermani, Stefania Bartolini, Alicia Tosoni, Eugenio Pozzati, Enrico Franceschi, Giovanni Tallini, Claudio Ghimenton, Luca Morandi, Rosalba Poggi, Alba A. Brandes, Antonella Bacci, Girolamo Crisi, A. Fioravanti
Přispěvatelé: Franceschi, Enrico, Ermani, Mario, Bartolini, Stefania, Bartolotti, Marco, Poggi, Rosalba, Tallini, Giovanni, Marucci, Gianluca, Fioravanti, Antonio, Tosoni, Alicia, Agati, Raffaele, Bacci, Antonella, Pozzati, Eugenio, Morandi, Luca, Balestrini, Damiano, Ghimenton, Claudio, Crisi, Girolamo, Brandes, Alba A.
Rok vydání: 2014
Předmět:
Oncology
Male
Cancer Research
Future studies
Databases
Factual
medicine.medical_treatment
Recurrence
Outcome Assessment
Health Care
Prospective Studies
Young adult
Prospective cohort study
DNA Modification Methylases
health care economics and organizations
Brain Neoplasms
DNA Repair Enzyme
Medicine (all)
Progression-free survival
Middle Aged
Combined Modality Therapy
Neurology
Disease Progression
Female
Human
Adult
medicine.medical_specialty
Adolescent
Endpoint Determination
education
End point
Second line chemotherapy
Disease-Free Survival
Brain Neoplasm
Outcome Assessment (Health Care)
Young Adult
Internal medicine
DNA Modification Methylase
Post-progression survival
medicine
Humans
Aged
Tumor Suppressor Protein
Chemotherapy
business.industry
Tumor Suppressor Proteins
Disease progression
DNA Methylation
medicine.disease
Surgery
Prospective Studie
DNA Repair Enzymes
Neurology (clinical)
business
Glioblastoma
Zdroj: Journal of neuro-oncology. 121(2)
ISSN: 1573-7373
Popis: The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥ 18 years; PS: 0-2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18-77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1-2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3-26.9 %). The median PPS was 8.6 months (95 % CI 7.4-9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3-72.9 %), PPS-9: 48.2 % (95 % CI 41.5-54.9 %) and PPS-12: 31.7 % (95 % CI 25.2-38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.
Databáze: OpenAIRE
Externí odkaz: